Skip to content

Study · Randomized controlled trial · n = 167 · 2011

8 results

Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.

Linnebjerg H, Kothare PA, Seger M, Wolka AM, Mitchell MI

International journal of clinical pharmacology and therapeutics1 Feb 2011Cited by 22 (Europe PMC)

PMID21255526 (opens in a new tab)DOI10.5414/cp201361 (opens in a new tab)PepBankPUB-21255526
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In both age groups with T2D, exenatide dose-dependently reduced postprandial glucose excursions.

    In plain wordsIn both age groups with T2D, exenatide reduced glucose rises after meals in a dose-dependent manner.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial glucose excursions
    Study

    n = 30

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 or 10 μg · subcutaneous · single dosesAs given in this study (human).

    Source sentences

    Summary
    Exenatide dose-dependently blunted postprandial serum glucose excursions in both age groups.
    2 context sentences
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.
  2. 02HumanRandomized controlled trialSafety outcome

    In both age groups with T2D, no hypoglycemia was reported during exenatide testing.

    In plain wordsIn both age groups with T2D, no low blood sugar was reported during exenatide testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableHypoglycemia
    Study

    n = 30

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    5 or 10 μg · subcutaneous · single dosesAs given in this study (human).

    Source sentences

    Summary
    No hypoglycemia or serious adverse events were reported, and exenatide was generally well tolerated in both age groups.
    2 context sentences
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.
  3. 03HumanRandomized controlled trialSafety outcome

    In both age groups with T2D, no serious adverse events were reported during exenatide testing.

    In plain wordsIn both age groups with T2D, no serious adverse events were reported during exenatide testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSerious adverse events
    Study

    n = 30

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    5 or 10 μg · subcutaneous · single dosesAs given in this study (human).

    Source sentences

    Summary
    No hypoglycemia or serious adverse events were reported, and exenatide was generally well tolerated in both age groups.
    2 context sentences
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.
  4. 04HumanRandomized controlled trialSafety outcome

    Exenatide was generally well tolerated in both age groups with T2D.

    In plain wordsExenatide was generally well tolerated in both age groups with T2D.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableTolerability
    Study

    n = 30

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    5 or 10 μg · subcutaneous · single dosesAs given in this study (human).

    Source sentences

    Summary
    No hypoglycemia or serious adverse events were reported, and exenatide was generally well tolerated in both age groups.
    2 context sentences
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.
  5. 05HumanObservational studyPharmacokinetics

    In integrated clinical data, exenatide apparent clearance showed a significant linear relationship with renal clearance.

    In plain wordsIn pooled clinical data, exenatide clearance had a significant relationship with kidney clearance.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableClearance relationship with renal clearance
    Study

    n = 167

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The integrated pharmacokinetic analysis showed a significant linear relationship between plasma exenatide CL/F and renal clearance (test of slope = 0, p < 0.001),with no additional effect from age.
    3 context sentences
    Summary · context
    Serial blood samples were collected for plasma exenatide and serum glucose concentrations.Pharmacokinetic data from this study were also integrated with those from six other clinical pharmacology studies to further evaluate the impact of age on plasma exenatide apparent clearance (CL/F) (139 control…
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.
  6. 06HumanObservational studyPharmacokinetics

    In integrated clinical data, age had no additional effect on exenatide clearance after renal clearance.

    In plain wordsIn pooled clinical data, age had no additional effect on exenatide clearance after kidney clearance.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAge effect on clearance
    Study

    n = 167

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The integrated pharmacokinetic analysis showed a significant linear relationship between plasma exenatide CL/F and renal clearance (test of slope = 0, p < 0.001),with no additional effect from age.
    3 context sentences
    Summary · context
    Serial blood samples were collected for plasma exenatide and serum glucose concentrations.Pharmacokinetic data from this study were also integrated with those from six other clinical pharmacology studies to further evaluate the impact of age on plasma exenatide apparent clearance (CL/F) (139 control…
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.
  7. 07HumanObservational studyPharmacokinetics

    In elderly patients with T2D, dose-normalized exenatide maximum concentration was higher, but not significantly different from younger controls.

    In plain wordsIn elderly patients with T2D, exenatide peak levels did not differ significantly from younger controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDose-normalized maximum concentration
    Study

    n = 30

    Comparator
    Patients aged ≥45 to ≤65 years
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    5 or 10 μg · subcutaneous · single dosesAs given in this study (human).

    Source sentences

    Summary
    Dose-normalized plasma exenatide maximum concentration and exposure were greater in elderly patients, but between-age group differences were neither statistically significant nor considered clinically relevant.
    2 context sentences
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.
  8. 08HumanObservational studyPharmacokinetics

    In elderly patients with T2D, dose-normalized exenatide exposure was higher, but not significantly different from younger controls.

    In plain wordsIn elderly patients with T2D, exenatide exposure did not differ significantly from younger controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDose-normalized exposure
    Study

    n = 30

    Comparator
    Patients aged ≥45 to ≤65 years
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    5 or 10 μg · subcutaneous · single dosesAs given in this study (human).

    Source sentences

    Summary
    Dose-normalized plasma exenatide maximum concentration and exposure were greater in elderly patients, but between-age group differences were neither statistically significant nor considered clinically relevant.
    2 context sentences
    Summary · context
    This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D.
    Summary · context
    Patients were randomized to single subcutaneous doses of exenatide 5μg, placebo or exenatide 10 μg (Sequence 1) or placebo, exenatide 5 μg or exenatide 10 μg (Sequence 2) before a standardized breakfast over three consecutive days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.